2013 Annual Meeting | Contemporary Clinical Issues Plenary Session
| 09:05 AM - 09:20 AM |
Radiologically Isolated Syndrome (RIS): 5-Year Risk for an Initial Clinical Event from a Multinational Cohort
Darin T. Okuda, MD, FAAN |
|
| 09:20 AM - 09:35 AM |
Discussant: Radiologically Isolated Syndrome (RIS): 5-Year Risk for an Initial Clinical Event from a Multinational Cohort
David H. Miller, MD, MBChB, FRCP |
|
| 09:35 AM - 09:50 AM |
Medical Management with mTOR Inhibitors vs. Surgical Resection: Comparison of Clinical Outcomes for Subependymal Giant Cell Astrocytoma (SEGA) in Tuberous Sclerosis Complex (TSC)
Susanne Yoon, MD |
|
| 09:50 AM - 10:05 PM |
Discussant: Medical Management with mTOR Inhibitors vs. Surgical Resection: Comparison of Clinical Outcomes for Subependymal Giant Cell Astrocytoma (SEGA) in Tuberous Sclerosis Complex (TSC)
David Viskochil, MD, PhD |
|
| 10:05 AM - 10:20 AM |
Clinicopathologic Correlations in 172 Cases of REM Sleep Behavior Disorder ± a Coexisting Neurologic Disorder
Bradley F. Boeve, MD, FAAN |
|
| 10:20 AM - 10:35 PM |
Discussant: Clinicopathologic Correlations in 172 Cases of REM Sleep Behavior Disorder ± a Coexisting Neurologic Disorder
Ronald Postuma, MD |
|
| 10:35 AM - 10:55 AM |
Brain Tumor Classification in Drug Development and Clinical Trials
Ingo K. Mellinghoff, MD, FACP |
|
| 10:55 AM - 11:15 AM |
Chronic Traumatic Encephalopathy
Daniel P. Perl, MD |
|
| 11:15 AM - 11:35 AM |
Functional Plasticity in MS
Maria A. Rocca |
| Bradley F. Boeve, MD, FAAN | Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care. |
| Susanne Yoon, MD | No disclosure on file |
| Ronald Postuma, MD | Dr. Postuma has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche, Biogen, Takeda, Theranexus, GE, Jazz, Curasen, Paladin, Inception Sciences, Phytopharmics, Vaxxinity, Merck. Dr. Postuma has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen/Partners. The institution of Dr. Postuma has received research support from CIHR, Weston Foundation, Webster Foundation, Roche, MJFF, Parkinson Canada, FRSQ, NIH. |
| Darin T. Okuda, MD, FAAN | Dr. Okuda has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Okuda has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Cortechs AI. Dr. Okuda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Okuda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Okuda has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Okuda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Moderna. Dr. Okuda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for RVL Pharmaceuticals, Inc.. Dr. Okuda has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Okuda has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Okuda has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Zenas BioPharma. Dr. Okuda has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. The institution of Dr. Okuda has received research support from Novartis. The institution of Dr. Okuda has received research support from EMD Serono. Dr. Okuda has received intellectual property interests from a discovery or technology relating to health care. |
| David H. Miller, MD, MBChB, FRCP | No disclosure on file |
| Maria A. Rocca | Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. The institution of Maria Assunta Rocca has received research support from MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. |
| David Viskochil, MD, PhD | The institution of David Viskochil, MD, PhD has received research support from Astellas. The institution of David Viskochil, MD, PhD has received research support from Takeda. The institution of David Viskochil, MD, PhD has received research support from Springworks. The institution of David Viskochil, MD, PhD has received research support from NFlection. |
| Ingo K. Mellinghoff, MD, FACP | Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Agios. Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Black Diamond Therapeutics. Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Voyager Therapeutics . Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kazia Therapeutics. Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Servier . Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Agios. Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Black Diamond Therapeutics. Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Debiopharm Group. Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Puma Biotechnology. Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Voyager Therapeutics. Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DC Europa Ltd. Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kazia Therapeutics. Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis . Dr. Mellinghoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cardinal Health. Dr. Mellinghoff has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Servier . Dr. Mellinghoff has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for ASCO/JCO. The institution of Dr. Mellinghoff has received research support from Amgen. The institution of Dr. Mellinghoff has received research support from General Electric. The institution of Dr. Mellinghoff has received research support from Lilly. The institution of Dr. Mellinghoff has received research support from Kazia Therapeutics. An immediate family member of Dr. Mellinghoff has received research support from Vigeo Therapeutics. The institution of an immediate family member of Dr. Mellinghoff has received research support from Samus Therapeutics. The institution of Dr. Mellinghoff has received research support from Erasca . |
| Daniel P. Perl, MD | No disclosure on file |